The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799544 (ARRY-134) AS A SINGLE AGENT AND IN COMBINATION WITH PF-07799933 BRAF DIMER INHIBITOR, IN PARTIC
Beck T, Shepard D, Dumas O, Pezo R, Rose A, Ong M, Saleh R, Iwamoto F, Gray J, Wollenberg L, Maity A, Sturtz K
MEK Brain Penetrant Inhibitor | June 1, 2024 | ASCO 2024
C4901001 | NCT05538130
